Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus

Karen H Costenbader; Elizabeth W Karlson; Victoria Gall; Paola de Pablo; Axel Finckh; Marsha Lynch; Bonnie Bermas; Peter H Schur; Matthew H Liang

doi:10.1002/art.21441

Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus

Karen H Costenbader
, Elizabeth W Karlson
, Victoria Gall
, Paola de Pablo
, Axel Finckh
, Marsha Lynch
, Bonnie Bermas
, Peter H Schur
, Matthew H Liang

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

37 Citations (Scopus)

Abstract

The effectiveness of aggressive management of traditional risk factors for accelerated atherosclerosis in systemic lupus erythematosus (SLE) has been advocated but not proven. We conducted a pilot, randomized, controlled trial of known prevention medications (pravastatin, ramipril, aspirin, and a combination B vitamin) plus individualized cardiovascular prevention education. We describe our experience in recruiting and retaining patients with SLE in this trial.

Original language	English
Pages (from-to)	718-23
Number of pages	6
Journal	Arthritis & Rheumatism
Volume	53
Issue number	5
DOIs	https://doi.org/10.1002/art.21441
Publication status	Published - 15 Oct 2005

Keywords

Anticholesteremic Agents
Antihypertensive Agents
Arteriosclerosis
Aspirin
Drug Therapy, Combination
Female
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Patient Dropouts
Patient Selection
Pilot Projects
Pravastatin
Ramipril
Treatment Refusal
Vitamin B Complex

Access to Document

10.1002/art.21441

Cite this

@article{eebb554991f44613a4714c2810f3fd4e,

title = "Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus",

abstract = "The effectiveness of aggressive management of traditional risk factors for accelerated atherosclerosis in systemic lupus erythematosus (SLE) has been advocated but not proven. We conducted a pilot, randomized, controlled trial of known prevention medications (pravastatin, ramipril, aspirin, and a combination B vitamin) plus individualized cardiovascular prevention education. We describe our experience in recruiting and retaining patients with SLE in this trial.",

keywords = "Anticholesteremic Agents, Antihypertensive Agents, Arteriosclerosis, Aspirin, Drug Therapy, Combination, Female, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Patient Dropouts, Patient Selection, Pilot Projects, Pravastatin, Ramipril, Treatment Refusal, Vitamin B Complex",

author = "Costenbader, \{Karen H\} and Karlson, \{Elizabeth W\} and Victoria Gall and \{de Pablo\}, Paola and Axel Finckh and Marsha Lynch and Bonnie Bermas and Schur, \{Peter H\} and Liang, \{Matthew H\}",

year = "2005",

month = oct,

day = "15",

doi = "10.1002/art.21441",

language = "English",

volume = "53",

pages = "718--23",

journal = "Arthritis \& Rheumatism",

issn = "0004-3591",

publisher = "Wiley",

number = "5",

}

TY - JOUR

T1 - Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus

AU - Costenbader, Karen H

AU - Karlson, Elizabeth W

AU - Gall, Victoria

AU - de Pablo, Paola

AU - Finckh, Axel

AU - Lynch, Marsha

AU - Bermas, Bonnie

AU - Schur, Peter H

AU - Liang, Matthew H

PY - 2005/10/15

Y1 - 2005/10/15

N2 - The effectiveness of aggressive management of traditional risk factors for accelerated atherosclerosis in systemic lupus erythematosus (SLE) has been advocated but not proven. We conducted a pilot, randomized, controlled trial of known prevention medications (pravastatin, ramipril, aspirin, and a combination B vitamin) plus individualized cardiovascular prevention education. We describe our experience in recruiting and retaining patients with SLE in this trial.

AB - The effectiveness of aggressive management of traditional risk factors for accelerated atherosclerosis in systemic lupus erythematosus (SLE) has been advocated but not proven. We conducted a pilot, randomized, controlled trial of known prevention medications (pravastatin, ramipril, aspirin, and a combination B vitamin) plus individualized cardiovascular prevention education. We describe our experience in recruiting and retaining patients with SLE in this trial.

KW - Anticholesteremic Agents

KW - Antihypertensive Agents

KW - Arteriosclerosis

KW - Aspirin

KW - Drug Therapy, Combination

KW - Female

KW - Humans

KW - Lupus Erythematosus, Systemic

KW - Male

KW - Middle Aged

KW - Patient Dropouts

KW - Patient Selection

KW - Pilot Projects

KW - Pravastatin

KW - Ramipril

KW - Treatment Refusal

KW - Vitamin B Complex

U2 - 10.1002/art.21441

DO - 10.1002/art.21441

M3 - Article

C2 - 16208639

SN - 0004-3591

VL - 53

SP - 718

EP - 723

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

IS - 5

ER -

Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus

Abstract

Keywords

Access to Document

Fingerprint

Cite this